<DOC>
	<DOCNO>NCT02519712</DOCNO>
	<brief_summary>The purpose study test method bone marrow transplantation result temporary donor immune function . In word , donor immune cell give way allow attack leukemia briefly destroy immune system , `` reject . '' The investigator want test whether temporary donor immune function enough improve odds achieve remission without expose patient toxicity full bone marrow transplant . To , investigator use standard chemotherapy AML follow infusion donor stem cell . The donor family member haploidentically , half match , patient child sibling . Chemotherapy design treat AML strong enough prevent reject donor stem cell . The investigator follow patient see long donor stem cell stay . The study test whether process feasible result improve chance obtain remission .</brief_summary>
	<brief_title>Treatment Elderly AML Patients With Induction Chemotherapy Followed G-CSF-Mobilized Stem Cells From Haploidentical Related Donors</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Age ≥ 60 . Patients new diagnosis histologically confirm ( accord WHO classification 2008 ) acute myeloid leukemia ( either primary secondary AML ) include . Patients diagnosis myelodysplastic syndrome &gt; /= 10 % bone marrow blast response progression disease least 4 cycle hypomethylating agent ( 5azacytiine decitabine ) . Patients must healthy bloodrelated donor ( parent , child , sibling ) willing undergo apheresis GCSF administration . Karnofsky performance status &gt; 70 % . Hepatic function total bilirubin &lt; 2 , AST &lt; 2.5 x upper limit normal , unless liver involved disease history Gilbert 's disease . Renal function adequate renal function demonstrate serum creatinine &lt; 2 mg/dl . LVEF ≥ 50 % determine echocardiogram MUGA . Ability give inform consent . Donor Eligibility : Donor bloodrelated HLAhaploidentical recipient . Donor ≥18 year old Donor undergone serologic test transmissible disease per blood banking guideline organ tissue donor . Tests include limited : HepBsAg , HepBsAb , HepBcAb , HepC antibody , HIV , HTLV I II , VZV , CMV VDRL , West Nile Virus . Donor must normal negative test result HIV , HTLV I II , West Nile Virus . Donor CXR EKG perform . Donor allergic GCSF . Donor must able undergo leukapheresis Donor pregnant . Donor concurrent malignancy autoimmune disease . Ability give inform consent . Patients diagnosis acute promyelocytic leukemia ( accord WHO classification 20080 Major surgery irradiation within two week . Previous therapy cytotoxic agent AML . Persons previous treatment myelodysplasia/myeloproliferation hydroxyurea , interferon , hypomethylating agent ( 5azacitidine decitabine ) , lenalidomide , JAK/STAT inhibitor may participate must &gt; 1 week therapy prior enrollment . Active CNS disease . Uncontrolled infection . Pregnant lactate woman exclude , give potential teratogenic effect chemotherapy agent use therapy . Male female patient childbearing potential unwilling use effective mean contraception . HIV HTLV I/II seropositivity . Concurrent active malignancy AML require therapy . Clinically significant cardiac disease ( NY Heart Association Class III IV ) pulmonary disease . Inability unwillingness comply treatment protocol , followup , research test Donor Exclusion : Donor cardiac risk factor preclude ability undergo leukapheresis . Donor evidence concurrent malignancy autoimmune disease . Donor pregnant</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Induction Chemotherapy</keyword>
	<keyword>G-CSF-Mobilized Stem Cells</keyword>
	<keyword>Haploidentical Related Donors</keyword>
	<keyword>15-141</keyword>
</DOC>